Pathological complete response in an advance stage IIIB non ‐small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature

The use of osimertinib as a safe and effective neoadjuvant targeted therapy for potentially resectable advance non-small cell lung carcinoma. AbstractNeoadjuvant chemotherapy is a therapeutic option for potentially resectable non-small cell lung cancer (NSCLC). The role of neoadjuvant targeted therapy (NTT) remains less explored. This case highlights the use of neoadjuvant osimertinib in a case of advanced NSCLC. A 67-year-old woman had a left lower lobe lung mass measuring 5.0  × 5.1 × 7.0 cm with an enlarged subcarinal lymph node (LN) on her positron emission tomography scan. Following biopsy, a diagnosis of stage IIIB N2 (cT3N2M0) EGFR exon 19 deletion mutation-positive lung adenocarcinoma was established. NTT using osimertinib 80 mg once daily was commenc ed. Subsequent re-imaging at 3 months (ycT2bN2M0), 6 months (ycT1cN2M0) and 9 months showed tumour downstaging and resolution of the subcarinal LN (ycT1cN0M0). She underwent left lower lobectomy with systematic nodal dissection. All surgical specimens demonstrated no evidence of malignant cells (ypT 0N0). Osimertinib could be the preferred NTT for potentially resectable NSCLC.

Source: Respirology Case Reports - June 21, 2023 Category: Respiratory Medicine Authors: Chun Ian Soo, Diana Bee ‐Lan Ong, Ka Kiat Chin, Leng Cheng Sia, Vijayan Munusamy, Nur Husna Ibrahim, Thian Chee Loh, Jiunn Liang Tan, Mau Ern Poh, Chee Kuan Wong, Yong Kek Pang, Chong Kin Liam Tags: CASE REPORT Source Type: research